| Literature DB >> 31023234 |
Xing Hu1, Xiaojie Huang2, Hui Chen3, Tong Zhang2, Jianhua Hou2, Aixin Song2, Lei Ding1, Weiyuan Liu1, Hao Wu4, Fankun Meng5.
Abstract
BACKGROUND: Shear wave elastography (SWE) imaging have been proposed for characterization of focal liver lesions. We conducted a meta-analysis to evaluate the accuracy and clinical utility of SWE imaging for differentiation of malignant and benign hepatic lesions.Entities:
Keywords: Diagnosis; Elasticity imaging techniques; Liver neoplasms; Meta-analysis; Ultrasonography
Mesh:
Year: 2019 PMID: 31023234 PMCID: PMC6485138 DOI: 10.1186/s12876-019-0976-2
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1Flow chart of study selection process
Main characteristics of the included studies
| Author,year | Country | Elastography modality | Instrument | No.of patients | No.of liver lesions (Malignant) | Invalid measures(%) | Lesion types | Reference standard | Cut-off value (SWE/SWV ratio) |
|---|---|---|---|---|---|---|---|---|---|
| Cho et al., 2010 [ | Korea | pSWE | Siemens, ACUSON S2000 | 51 | 60(43) | 21.7% | HCC,CCC,LM,haemangioma | histopathology, CT/MRI | 2 m/s |
| Davies et al., 2011 [ | Holland | pSWE | Siemens, ACUSON S2000 | 37 | 45(10) | NR | haemangioma,LM | biopsy,CT/MRI | 2.5 m/s (1.6) |
| Shuang-Ming et al., 2011 [ | China | pSWE | Siemens, ACUSON S2000 | 116 | 128(68) | 22.7% | HCC, CCC,LM, haemangioma,FNH,RN,FFS,FFC,abscess,adenoma,SNN | histopathology, CT/MRI | 2.22 m/s |
| Yu et al., 2011 [ | Canada | pSWE | Siemens, ACUSON S2000 | 89 | 105(41) | 6.1% | HCC,LM,haemangioma,FNH,FFS,FFD,adenoma | biopsy, CT/MRI | 1.9 m/s |
| Kapoor et al., 2011 [ | India | pSWE | Siemens, ACUSON S2000 | 42 | 42(27) | 12.5% | HCC,LM,haemangiomas,lymphomas,FNH,sarcoid,abscesses,FFS | biopsy | 2.5 m/s |
| Kim et al., 2013 [ | Korea | pSWE | Siemens, ACUSON S2000 | 74 | 101(73) | NR | HCC,CCC,LM, hemangioma | pathology, CT/MRI | 2.73 m/s |
| Park et al., 2013 [ | Korea | pSWE | Siemens, ACUSON S2000 | 47 | 47(39) | 20% | HCC,CCC,LM,haemangioma,FNH | histopathology, CT/MRI | 1.82 m/s |
| Zhang et al., 2014 [ | China | pSWE | Siemens, ACUSON S2000 | 156 | 170(112) | 9.7% | HCC,CCC,LM,hemangioma,FNH,RN | histopathology, CT/MRI,DSA | 2.16 m/s |
| Guo et al., 2015 [ | China | pSWE | Siemens, ACUSON S2000 | 134 | 134(55) | 11.0% | HCC,CCC,LM,hemangioma,focal fatty degeneration,FFS,FNH, abscess | pathology, CT/MRI | 2.13 m/s (1.37) |
| Lu et al., 2015 [ | China | pSWE(Elast PQ) | Philips iu22 | 259 | 259(201) | 1.2% | HCC,ICC,LM,hemangioma, FNH, CN | histopathology | 13Kpa (1.3) |
| Wu et al., 2016 [ | China | pSWE | Siemens, ACUSON S2000 | 46 | 55(27) | NR | HCC,LM,hemangioma,FFS,RN | pathology, CEUS, CT/MRI | 2.22 m/s |
| Dong et al., 2017 [ | China | pSWE(ElastPQ) | Philips EPIQ7 | 154 | 154(129) | NR | HCC,ICC,CHC,sarcoma,LM,AML,FNH,hemangioma,IPT | histopathology | 2.06 m/s (1.67) |
| Wen-Shuo et al., 2016 [ | China | 2D-SWE(SuperSonic Imagine) | Aixplorer | 221 | 229(164) | 6.6% | HCC,ICC,CHC,LM,sarcomaneuroendocrine cancer,Unclassified cancer,FNH,hemangioma,angioleiomyolipoma,cavernous vascular tumor,abscess,Inflammatory pseudo-tumor,inflammation,solitary fibroma | histopathology,CEUS | Emax39.60Kpa/ |
| Gerber et al., 2017 [ | Germany | 2D-SWE(SuperSonic Imagine) | Aixplorer | 106 | 106(64) | 24.3% | haemangioma,FNH, adenoma,FFS, RN,cholangiofibroma, HCC,CCC, LM | histopathology,CEUS, CT/MRI | Emean20.7 Kpa |
| Grgurevic et al., 2018 [ | Switzerland | 2D-SWE(SuperSonic Imagine) | Aixplorer | 196 | 259(168) | 26.3% | HCC,CCC,LM,haemangioma, FNH | biopsy, CT/MRI | Emean22.3 Kpa |
No number, HCC hepatocellular carcinoma, ICC intrahepatic cholangiocellular carcinoma, CCC cholangiocarcinoma, CHC Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma, LMN liver metastasis, FNH focal nodular hyperplasia, FFS focal fatty sparing/ nodule of focal fatty sparing, FFD focal fat deposits, FFC focal fatty change, SNN solitary necrotic nodule, RN regenerative node, CN cirrhotic nodule, AML hepatic angiomyolipoma, IPT inflammatory pseudotumor, CT computer tomography, MRI magnetic resonance imaging, CEUS contrast enhanced ultrasound, MRI; DSA digital subtraction angiography, NR not reported
Fig. 2Quality assessment of the included studies according to Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) criteria
Fig. 3Sensitivity and specificity forest plots of shear wave elastography for differentiation of malignant and benign liver lesions. The pooled sensitivity and specificity of the SWE for differentiation of malignant and benign malignant liver lesions were 0.82 (95%CI: 0.77–0.86) and 0.82 (95%CI: 0.76–0.87), respectively
Fig. 4HSROC curve for differentiation of malignant and benign liver lesions of (a) shear wave elastography, (b) the shear wave velocity ratio (FLL to surrounding liver parenchyma). The AUC of the SWE and the SWV ratio for differentiation of malignant and benign malignant liver lesions were 0.89 (95%CI: 0.86–0.91) and 0.78 (95%CI: 0.74–0.81), respectively. (HSROC: Hierarchical summary receiver operating characteristic; FLL: focal liver lesion; PLR: positive likelihood ratio; NLR: negative likelihood ratio; DOR: diagnostic odds ratio; AUC: area under the curve)
Results of the meta-regression and subgroup analyses on shear wave elastography for differentiation of malignant and benign liver lesions
| Covariates | Subgroup | No.of studies | Pooled SEN | Pooled SPE | Meta-Regression Joint | ||
|---|---|---|---|---|---|---|---|
| modality | 1-pSWE | 12 | 0.82(0.76–0.87) | <0.01 | 0.83(0.77–0.89) | 0.18 | 0.70 |
| 0-2D-SWE | 3 | 0.84(0.75–0.93) | 0.79(0.66–0.92) | ||||
| location | 1-Asian | 11 | 0.82(0.77–0.88) | 0.02 | 0.82(0.76–0.89) | 0.05 | 0.99 |
| 0- European or North America | 4 | 0.82(0.72–0.92) | 0.81(0.71–0.92) | ||||
| gold standard | 1-histopathology | 3 | 0.82(0.72–0.92) | 0.02 | 0.85(0.73–0.96) | 0.22 | 0.89 |
| 0- histopathology and/or other | 12 | 0.82(0.77–0.88) | 0.81(0.75–0.88) | ||||
| number of lesions | 1- ≥ 100 | 10 | 0.84(0.79–0.88) | 0.06 | 0.80(0.73–0.86) | <0.01 | 0.10 |
| 0-<100 | 5 | 0.76(0.66–0.87) | 0.88(0.80–0.97) | ||||
| prevalence of malignant lesions | 1- ≥ 50% | 11 | 0.84(0.79–0.88) | 0.14 | 0.81(0.74–0.88) | 0.02 | 0.29 |
| 0-<50% | 4 | 0.75(0.63–0.87) | 0.84(0.74–0.94) | ||||
| blinded | 1-yes | 11 | 0.82(0.77–0.88) | 0.02 | 0.81(0.74–0.88) | 0.02 | 0.79 |
| 0-unclear | 4 | 0.82(0.72–0.92) | 0.85(0.75–0.95) | ||||
| attrition rate | 1- ≥ 10% | 7 | 0.82(0.77–0.87) | <0.01 | 0.81(0.74–0.88) | 0.04 | <0.01 |
| 0-<10% | 4 | 0.80(0.75–0.86) | 0.78(0.69–0.87) |
SEN sensitivity, SPE specificity
Fig. 5Fagan plot to evaluate the clinical utility of shear wave elastography for differentiation of liver lesions. (A) Pre-test probability = 25%; (B) Pre-test probability = 50%; (C) Pre-test probability = 75%. When the pre-test probability was 25%, with 60% probability of malignant disease following a positive measurement, and the probability reduced to 7% when a negative measurement occurred (Fig. a). When the pre-test probability was 50%, with 82% probability of malignant disease following a positive measurement, and the probability reduced to 18% when a negative measurement occurred (Fig. b). When the pre-test probability was 75%, with 93% probability of malignant disease following a positive measurement, and the probability reduced to 39% when a negative measurement occurred (c). (PLR: positive likelihood ratio; NLR: negative likelihood ratio)